Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...
Researchers analyzed BTH definition, frequency, and severity across phase 3 clinical trials with terminal complement inhibitors (ravulizumab and crovalimab) and upstream complement inhibitors ...
Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...
-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results